Rate My Professor Jeremy Ruben

Adjunct Associate Professor Jeremy Ruben is a radiation oncologist based at Alfred Health Radiation Oncology and an Adjunct Associate Professor in the School of Translational Medicine at Monash University. He qualified in medicine cum laude with an MBBCh (Hons) in 1994, obtained specialist radiation oncology qualifications including FCRadOnc (South Africa) in 2003 and FRANZCR (Australia) in 2006, a Master of Medicine (MMed) in 2007 with a thesis on Intensity Modulated Radiotherapy, and a Doctor of Medicine (MD) from Monash University in 2015. Ruben completed clinical oncology training in medical and radiation oncology, followed by a fellowship in advanced radiotherapy techniques at The William Buckland Radiotherapy Centre at The Alfred Hospital. He holds clinical appointments at GenesisCare and Cabrini Health, heads the Stereotactic Radiosurgery service, and serves as lead clinician for lung and central nervous system (CNS) tumors at The Alfred.

Since 2009, Ruben has been Director of Training at The Alfred, inaugural Training Network Director for RANZCR in Victoria and Tasmania for 11 years, and an examiner for RANZCR final specialist exams for 11 years. He is a founding member and executive of the RANZCR Faculty of Radiation Oncology Lung Interest Group, a member of the Trans-Tasman Radiation Oncology Group (TROG) stereotactic working group, and serves on the scientific advisory committee for the Cooperative Trials Group for Neuro-Oncology (COGNO), previously for the Australian Lung Cancer Trials Group (TOGA/ALCTG). His research interests encompass neuro-oncology, stereotactic ablative body radiotherapy (SABR/SBRT), lung cancer, melanoma, spine, and oligometastatic disease. Key publications include 'Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL)' (The Lancet Oncology, 2019), 'Cerebral radiation necrosis: incidence, outcomes, and risk factors' (International Journal of Radiation Oncology Biology Physics, 2006), 'Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II)' (The Lancet Oncology, 2024), and 'Management and outcomes of glioblastoma: 20-year experience in a single Australian institution' (Journal of Medical Imaging and Radiation Oncology, 2024). With over 40 publications, he has authored Australian national lung cancer guidelines, contributed to eviQ guidelines, served as chief or associate investigator on NHMRC and Cancer Council Australia grants for clinical trials, and presented as an invited speaker at conferences.